Neurogene FY Conference Summary Company Overview - **Company**: Neurogene (NasdaqGM:NGNE) - **Focus**: Development of genetic medicines for neurological diseases, specifically targeting Rett syndrome with their lead program NGN-401 [1][2] Core Points and Arguments Rett Syndrome and Market Opportunity - Rett syndrome is a severe neurological disorder primarily affecting girls, with an estimated 15,000-20,000 patients in the U.S. and Europe, representing a multi-billion dollar market opportunity for genetic treatments [3] - The company is actively progressing towards the commercialization of NGN-401, with ongoing Phase 3 trial (Embolden) enrollment expected to complete in Q2 2026 [3][4] EXACT Platform - The EXACT platform is designed to control gene expression levels, specifically the MECP2 transgene, which is crucial for preventing Rett syndrome [5][6] - The platform includes a microRNA-based safety valve to regulate transgene expression, avoiding toxic levels [6] Breakthrough Therapy Designation - Neurogene received Breakthrough Therapy designation from the FDA based on encouraging Phase 1-2 trial results, including new patient-level data and video evidence demonstrating skill gains [4][8][9] Clinical Trial Insights - The primary endpoint of the Embolden trial includes video-based documentation of skill gains and developmental milestones [16] - The Phase 1-2 trial showed a time-dependent improvement in function, with patients gaining skills over time rather than just stabilizing [18][27] - The trial has reported an increase in developmental milestones from 23 to 35 across 8 patients, indicating a deepening effect over time [61][172] Safety and Monitoring - The company has implemented safety protocols, including monitoring for HLH (Hemophagocytic Lymphohistiocytosis), which was previously observed at higher doses but has not occurred at current dosing levels [180][185] - No cases of HLH have been reported in the ongoing trials, indicating effective safety measures [185] Regulatory Considerations - Neurogene emphasizes the importance of a 12-month primary endpoint for the Embolden study, arguing that the FDA and caregivers prefer more data for assessing long-term benefits [192] - The company believes that a 12-month assessment is necessary for understanding the benefit-risk profile of gene therapies for Rett syndrome [192] Other Important Content - The company is focused on establishing a commercialization pathway and engaging with payers to support the launch of NGN-401 [4] - The commitment of families involved in the trial is highlighted, as they are already engaged in physical and occupational therapies to maximize outcomes for their children [95] - The company is optimistic about the long-term data from the trial, which will be valuable for various stakeholders, including caregivers, payers, and regulators [112][188] This summary encapsulates the key points discussed during the Neurogene FY Conference, focusing on the company's advancements in gene therapy for Rett syndrome, the significance of their EXACT platform, and the ongoing clinical trials.

Core Viewpoint - Acadia Pharmaceuticals faces a regulatory setback as the European Medicines Agency's CHMP has issued a negative opinion against the approval of trofinetide for treating Rett syndrome in the EU [1][6]. Regulatory Developments - The negative opinion from CHMP was anticipated following an early February notification of a negative trend vote on the marketing application for trofinetide [2]. - Acadia plans to request a re-examination of the CHMP's decision after reviewing the grounds for refusal [2][6]. Clinical Study Insights - The pivotal LAVENDER study met its co-primary and key secondary endpoints; however, CHMP cited limitations such as the modest treatment effect after 12 weeks and incomplete capture of core symptoms of Rett syndrome [3][6]. - Concerns were raised regarding the assessment of long-term outcomes due to patient discontinuations over time [3]. Market Context - Rett syndrome is a rare neurodevelopmental disorder affecting approximately one in 10,000-15,000 female births globally [4]. - The FDA approved trofinetide as the first and only treatment for Rett syndrome in the U.S. in 2023, marketed as Daybue [5]. Financial Outlook - Despite the regulatory hurdle, Acadia is positioned for long-term growth, expecting combined net sales of around $1.7 billion by 2028, with $1 billion from Nuplazid and $700 million from Daybue [7]. - Nuplazid, the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, recorded $680.1 million in sales in 2025, reflecting a 12% year-over-year increase [8]. - Daybue has also shown promising sales uptake, with $391.4 million in sales in 2025, marking a 12% year-over-year growth [9]. Product Developments - The FDA approved Daybue Stix, a new formulation of trofinetide, for oral solution in late 2025, expanding the Daybue franchise [10]. - Acadia plans a limited launch of Daybue Stix in Q1 2026, with broader availability expected in Q2 [11][13].

Core Viewpoint - Anavex Life Sciences Corp. is advancing its clinical pipeline, particularly focusing on its lead candidate, oral blarcamesine, for early Alzheimer's disease, with a commitment to improving the lives of patients with neurological disorders [2][3]. Financial Highlights - Cash and cash equivalents increased to $131.7 million as of December 31, 2025, compared to $102.6 million at September 30, 2025, indicating a cash runway of more than 3 years at the current utilization rate [11]. - Research and development expenses for the quarter were $4.7 million, down from $10.4 million in the comparable quarter of fiscal 2025 [11]. - General and administrative expenses decreased to $2.1 million from $3.1 million in the same period last year [11]. - The net loss for the quarter was $5.7 million, or $0.06 per share, compared to a net loss of $12.1 million, or $0.14 per share for the comparable fourth quarter of fiscal 2025 [11]. Recent Corporate Developments - Anavex is making progress on its clinical development program for Parkinson's disease and has updates on regulatory pathways for blarcamesine in both early Alzheimer's disease and Rett syndrome [6]. - The company announced its participation in ACCESS-AD, a European initiative aimed at accelerating innovative diagnostic and therapeutic approaches for Alzheimer's disease [6]. - Wolfgang Liedtke, MD PhD, was appointed as Senior Vice President, Global Head of Neurology, bringing over 25 years of experience in CNS diseases [6]. Expected Development Milestones - Upcoming presentations include an oral presentation at the 16th Intrinsic Capacity, Frailty and Sarcopenia Research Conference, focusing on the treatment of older adults with pre-frailty using oral blarcamesine [6]. - Anavex plans to submit existing data from the Phase IIb/III ANAVEX2-73-AD-004 program to the FDA to support a New Drug Application for Alzheimer's disease [11].

Core Insights - Acadia Pharmaceuticals anticipates a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its marketing application for trofinetide to treat Rett syndrome [1][2] Company Overview - Acadia was informed of a negative trend vote on its marketing application for trofinetide, which may delay potential approval in the European Union [2] - The company plans to seek a re-examination of the CHMP opinion once it is formally adopted [2] Product Information - Trofinetide is intended for treating Rett syndrome, a rare neurodevelopmental disorder affecting approximately one in 10,000-15,000 female births globally [3] - The FDA approved trofinetide for treating Rett syndrome in adults and pediatric patients aged two years and older in 2023, marketed as Daybue in the United States [4] Financial Performance - Acadia's shares have increased by 8.6% over the past six months, while the industry has seen a rally of 18.8% [5] - The company expects long-term growth from its products Nuplazid and Daybue, targeting combined net sales of $1.7 billion by 2028, with approximately $1 billion from Nuplazid and $700 million from Daybue [8][9] Market Position - Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, with patent protection until 2038 [10] - In the first nine months of 2025, Nuplazid generated $505.7 million in sales, reflecting a 13% year-over-year increase [10] - Daybue has also shown promising sales, with $281.8 million in sales during the first nine months of 2025, up 12% year-over-year [11] New Product Launch - The FDA recently approved Daybue Stix, an oral solution for treating Rett syndrome, which will be launched in a limited capacity in Q1 2026, followed by broader availability in Q2 2026 [12][13]